Company profile
ALAUNOS THERAPEUTICS, INC.
NASDAQ:TCRTBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DARINAPARSIN | phase2 | — | 7 | completed, terminated, withdrawn |
| PALIFOSFAMIDE | phase2 | — | 3 | completed, terminated |
| VELEDIMEX | phase2 | — | 8 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (35)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00592046 | phase1 | completed | 2005-05-01 | 2008-06-01 | Alaunos Therapeutics | A Phase I Trial of ZIO-101 in Hematologic Cancers |
| NCT00591396 | phase1 | completed | 2005-07-01 | 2008-07-01 | Alaunos Therapeutics | A Phase I Trial of ZIO-101 in Solid Tumors |
| NCT00423644 | phase2 | completed | 2007-01-01 | 2007-12-21 | Alaunos Therapeutics | A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b |
| NCT00423306 | phase2 | terminated | 2007-05-01 | 2008-08-09 | Alaunos Therapeutics | A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma |
| NCT00421135 | phase1 | completed | 2006-02-01 | 2007-10-01 | Alaunos Therapeutics | A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer |
FDA applications (0)
No records yet.